Cadrenal Therapeutics, Inc. (CVKD) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.07

From 52W high−92.50%

Volume151988.00

Market cap$3.78M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.07

From 52W high

−92.50%

Volume

151988.00

Market cap

$3.78M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

46.8

MomentumView details →

1D Return

−2.75%

YTD Return

−84.37%

SummaryUpdated Jun 1, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Ponte Vedra, Florida. The company went public in January 2023 and focuses exclusively on developing a single therapeutic candidate called Tecarfarin, designed to address a critical unmet medical need in patients with end-stage kidney disease who also suffer from atrial fibrillation.

Ask drillr about Cadrenal Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−282.13%

ROA (TTM)

−206.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+44.88%

FCF YoY

+12.95%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+23.94%

EBITDA YoY

+18.02%

MomentumView details →

1D Return

−2.75%

YTD Return

−84.37%

1Y Return

−91.80%

RSI (14)

46.8

vs 50D SMA

−17.81%

vs 200D SMA

−75.08%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.73x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.14

EPS Surprise

19.72%

Beats (12Q)

3/12

Next Q EPS Est

−$0.86

Avg Surprise (4Q)

0.72%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.54M

Op. CF (TTM)

−10.16M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cadrenal Therapeutics, Inc. initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.13d ago

Cadrenal Therapeutics, Inc. appointed Quang X. Pham as a Class I director effective September 24, 2026.20d ago

Similar companies

KALA BIO, Inc.KALA Jupiter Neurosciences, Inc.JUNS ZyVersa Therapeutics, Inc.ZVSA PharmaCyte Biotech, Inc.PMCB NuCana plcNCNA OSR Holdings, Inc.OSRH Find similar companies →

Latest newsMore news →

Cadrenal Therapeutics, Inc. initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.13d ago Cadrenal Therapeutics, Inc. appointed Quang X. Pham as a Class I director effective September 24, 2026.20d ago